Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
characterized by demyelination and axonal degeneration. MS patients typically present with …

TBI is a nondegenerative, noncongenital insult to the brain from an external mechanical
force; for instance a violent blow in a car accident. It is a complex injury with a broad …

Primary progressive multiple sclerosis (PPMS) is a chronic demyelinating disease of the
central nervous system (CNS) currently lacking any effective treatment. Promoting …

Fast remyelination by endogenous oligodendrocyte precursor cells (OPCs) is essential to
prevent axonal and subsequent retrograde neuronal degeneration in demyelinating lesions …

Traumatic brain injury (TBI) has been recognized as one of the major public health issues
that leads to devastating neurological disability. As a consequence of primary and …

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, and demyelinating disorder
of the central nervous system (CNS), which ultimately leads to axonal loss and permanent …

Recent studies suggest that myeloperoxidase (MPO)-dependent oxidative stress plays a
significant role in brain injury in stroke patients. We previously showed that N-acetyl …

A very important cause of the frustration with drug therapy for central nervous system (CNS)
diseases is the failure of drug delivery. The blood–brain barrier (BBB) prevents most …

Multiple sclerosis (MS), a complex disorder of the central nervous system (CNS), is
characterized with axonal loss underlying long-term progressive disability. Currently …